Yoshimasa Mori

Yoshimasa Mori

Auto-generated profile, based on publicly available information

Yoshimasa Mori

Product Development Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc. , Osaka , Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Journal of Controlled Release
Verified
Journal Article
Closed access
HAHidetoshi Arima
Hidetoshi Arima
SYShogo Yamashita
Shogo Yamashita
YMYoshimasa Mori
Yoshimasa Mori
YHYuya Hayashi
Yuya Hayashi
KMKeiichi Motoyama
Keiichi Motoyama
KUKaneto Uekama
Kaneto Uekama

14 June 2011 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
HJHirofumi Jono
Hirofumi Jono
TATakayuki Anno
Takayuki Anno
KMKeiichi Motoyama
Keiichi Motoyama
YMYohei Misumi
Yohei Misumi
MTMasayoshi Tasaki
Masayoshi Tasaki
YAYusuke Ando
Yusuke Ando
TTR (transthyretin), a β-sheet-rich protein, is the precursor protein of familial amyloidotic polyneuropathy and senile systemic amyloidosis. Although it has been widely accepted that protein misfolding of the monomeric form of TTR is a rate-limiting step for amyloid formation, no effective therapy targeting this misfolding step is available. In the present study, we focused on CyDs (cyclodextrins), cyclic oligosaccharides composed of glucose units, and reported the inhibitory effect of CyDs on TTR amyloid formation. Of various branched β-CyDs, GUG-β-CyD [6-O-α-(4-O-α-D-glucuronyl)-D-glucosyl-β-CyD] showed potent inhibition of TTR amyloid formation. Far-UV CD spectra analysis showed that GUG-β-CyD reduced the conformational change of TTR in the process of amyloid formation. In addition, tryptophan fluorescence and 1H-NMR spectroscopy analyses indicated that GUG-β-CyD stabilized the TTR conformation via interaction with the hydrophobic amino acids of TTR, especially tryptophan. Moreover, GUG-β-CyD exerted its inhibitory effect by reducing TTR deposition in transgenic rats possessing a human variant TTR gene in vivo. Collectively, these results indicate that GUG-β-CyD may inhibit TTR misfolding by stabilizing its conformation, which, in turn, suppresses TTR amyloid formation.

9 April 2013 in Journal of Drug Targeting
Verified
Journal Article
Closed access
PDF file
YHYuya Hayashi
Yuya Hayashi
THTaishi Higashi
Taishi Higashi
KMKeiichi Motoyama
Keiichi Motoyama
YMYoshimasa Mori
Yoshimasa Mori
HJHirofumi Jono
Hirofumi Jono
HAHidetoshi Arima
Hidetoshi Arima
To develop a novel hepatocyte-selective gene carrier, we prepared polyamidoamine starburst dendrimer (generation 3, G3) conjugates with three functional molecules, i.e. α-cyclodextrin, polyethylene glycol (PEG, molecular weight = 2170) and lactose (PEG-LαCs), and evaluated gene delivery efficiency of these conjugates in vitro and in vivo. PEG-LαC (G3, degrees of substitution of the PEG moiety (DSP) 2.1) showed higher gene transfer activity than other PEG-LαCs (G3, DSP4.0, 6.2) in HepG2 cells, expressing asialoglycoprotein receptor, and the activity decreased in HeLa cells, non-expressing the receptor and in the presence of asialofetuin. High gene transfer activity of PEG-LαC (G3, DSP2.1) was retained even in the presence of 50% serum, although the activity of α-cyclodextrin/lactosylated dendrimer (G3) conjugate (Lac-α-CDE (G3)), which is lacking a PEG moiety, was severely decreased in the presence of 20% serum. PEG-LαC (G3, DSP2.1) provided negligible cytotoxicity up to a charge ratio of 50 (carrier/pDNA) in HepG2 cells and less acute organ toxicity. PEG-LαC (G3, DSP2.1) showed selective gene transfer activity to hepatic parenchymal cells rather than hepatic non-parenchymal cells. These results suggest that PEG-LαC (G3, DSP2.1) is useful as a hepatocyte-selective gene carrier in vitro and in vivo.

21 April 2012 in Amyloid
Verified
Journal Article
Closed access
PDF file
YHYuya Hayashi
Yuya Hayashi
YMYoshimasa Mori
Yoshimasa Mori
THTaishi Higashi
Taishi Higashi
KMKeiichi Motoyama
Keiichi Motoyama
HJHirofumi Jono
Hirofumi Jono
HAHidetoshi Arima
Hidetoshi Arima
RNA interference (RNAi) is a sequence-specific gene-silencing mechanism triggered by double-stranded RNA and powerful tools for a gene function study and RNAi therapy. Although siRNAs offer several advantages as potential new drugs to treat various diseases, the efficient delivery system of siRNAs in vivo remains a crucial challenge for achieving the desired RNAi effect in clinical development. In particular, when considering the siRNA therapeutics for familial amyloidotic polyneuropathy (FAP) caused by the deposition of variant transthyretin (TTR) in various organs, hepatocyte-selective siRNA delivery is desired because TTR is predominantly synthesized by hepatocytes. In this study, to reveal the potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugate (Lac-α-CDE (G3)) as novel hepatocyte-selective siRNA carriers in order to treat FAP, we evaluated the RNAi effect of siRNA complex with Lac-α-CDE (G3) both in vitro and in vivo.

1 January 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YMYoshimasa Mori
Yoshimasa Mori
KMKeiichi Motoyama
Keiichi Motoyama
MIMakoto Ishida
Makoto Ishida
RORisako Onodera
Risako Onodera
THTaishi Higashi
Taishi Higashi
HAHidetoshi Arima
Hidetoshi Arima

21 August 2010 in Journal of Inclusion Phenomena and Macrocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
KMKeiichi Motoyama
Keiichi Motoyama
YMYoshimasa Mori
Yoshimasa Mori
SYShogo Yamashita
Shogo Yamashita
YHYuya Hayashi
Yuya Hayashi
HJHirofumi Jono
Hirofumi Jono
HAHidetoshi Arima
Hidetoshi Arima